|
Hepatitis C Treatments PA Form 470-5270 456.71 KB |
|
2017/09/05 |
|
Insulin, Pre-Filled Pens PA Form 470-4111 27.38 KB |
|
2017/08/24 |
|
CNS Stimulants and Atomoxetine PA Form 470-4116 32.8 KB |
|
2017/08/24 |
|
Oral Constipating Agents PA Form 470-5174 33.63 KB |
|
2017/08/24 |
|
Eluxadoline (Viberzi) PA Form 470-5410 30.99 KB |
|
2017/08/24 |
|
Anti-Diabetic, Non-Insulin Agents PA Form 470-5259 26.22 KB |
|
2017/08/24 |
|
Angiotension Receptor Blocker Before ACE Inhibitor PA Form 470-4593 24.61 KB |
|
2017/08/24 |
|
Selected Brand Name Drug PA Form 470-5039 & 470-4119 43.17 KB |
|
2017/08/24 |
|
Serotonin 5-HT1-receptor Agonists PA Form 470-4113 25.15 KB |
|
2017/08/24 |
|
Deflazacort (Emflaza) PA Form 470-5489 25.98 KB |
|
2017/08/23 |
|
Crisaborole (Eucrisa) PA Form 470-5488 26.29 KB |
|
2017/08/23 |
|
GLP-1 Agonist/Basal Insulin Combinations PA Form 470-5490 24.77 KB |
|
2017/08/23 |
|
Sapropterin (Kuvan) PA Form 470-5493 64.98 KB |
|
2017/08/23 |
|
New to Market Drugs PA Form 470-5492 23.02 KB |
|
2017/08/23 |
|
Calcifediol (Rayaldee) PA Form 470-5487 24.57 KB |
|
2017/08/23 |
|
Lesinurad (Zurampic) PA Form 470-5491 68.3 KB |
|
2017/08/23 |
|
Eteplirsen (Exondys 51) PA Form 470-5476 236.33 KB |
|
2017/04/25 |
|
Antiemetic-5HT3 receptor Antogonists/Substance P Neurokinin Agents PA Form 470-4410 27.72 KB |
|
2017/04/25 |
|
Anti-Fungal PA Form 470-4094 23.77 KB |
|
2017/04/25 |
|
Novel Oral Anticoagulants PA Form 470-5423 101.27 KB |
|
2017/04/25 |
|
Modified Formulations PA Form 470-4705 24.55 KB |
|
2017/04/25 |
|
Lumacaftor/Ivacaftor (Orkambi) PA Form 470-5366 182.06 KB |
|
2017/04/25 |
|
Daclizumab (Zinbryta) PA Form 470-5462 184.18 KB |
|
2017/04/18 |
|
Fentanyl, Short Acting Products PA Form 470-4092 188.79 KB |
|
2017/04/18 |
|
Hepatitis C Post Treatment Information Sustained Virologic Response (SVR) Reporting PA Form 470-5463 237.5 KB |
|
2017/02/24 |
|
Narcan (Naloxone) Nasal Spray PA Form 470-5461 174.93 KB |
|
2017/02/20 |
|
Alpha 2 Agonist, Extended Release PA Form 470-5018 187.72 KB |
|
2017/02/20 |
|
Omalizumab (Xolair) PA Form 470-4279 245.81 KB |
|
2017/02/20 |
|
Multiple Sclerosis Agents - Oral PA Form 470-5060 266.76 KB |
|
2017/02/20 |
|
Duplicate Therapy Edit Override PA Form 470-5460 174.36 KB |
|
2017/02/07 |
|
Concurrent IM/PO Antipsychotic PA Form 470-4594 174.21 KB |
|
2017/02/07 |
|
Buprenophine/Naloxone PA Form 470-5142 198.32 KB |
|
2016/11/21 |
|
Testosterone Products PA Form 470-5188 220.89 KB |
|
2016/11/21 |
|
Biologicals for Ankylosing Spondylitis PA Form 470-4521 193.24 KB |
|
2016/11/21 |
|
Biologicals for Arthritis PA Form 470-4522 197.46 KB |
|
2016/11/21 |
|
Short Acting Opioids PA Form 470-4899 243.69 KB |
|
2016/11/21 |
|
Topical Acne and Rosacea Products PA Form 470-5426 195.56 KB |
|
2016/11/21 |
|
Lupron Depot - Adult PA Form 470-5435 248.74 KB |
|
2016/11/21 |
|
Biologicals for Plaque Psoriasis PA Form 470-4524 190.67 KB |
|
2016/11/21 |
|
Lupron Depot - Pediatric PA Form 470-5434 244.15 KB |
|
2016/11/21 |
|
Colchicine PA Form 470-5059 186.91 KB |
|
2016/11/21 |
|
Pulmonary Arterial Hypertension PA Form 470-4327 30.04 KB |
|
2016/08/23 |
|
Extended Release Formulation PA Form 470-4550 22.93 KB |
|
2016/08/19 |
|
Janus Kinase Inhibitors PA Form 470-5175 28.19 KB |
|
2016/08/19 |
|
Deferasirox (Exjade) PA Form 470-5330 64.2 KB |
|
2016/08/19 |
|
Mepolizumab (Nucala) PA Form 470-5424 67.76 KB |
|
2016/08/19 |
|
Potassium Binders PA Form 470-5425 25.16 KB |
|
2016/08/19 |
|
Nicotine Replacement Therapy 470-4421 193.75 KB |
|
2016/08/02 |
|
Smoking Cessation Therapy - Oral PA Form 470-4517 248.28 KB |
|
2016/08/02 |
|
Biologicals for Hidradenitis Suppurativa PA Form 470-5408 179.68 KB |
|
2016/06/22 |
|
Ivabradine (Corlanor) PA Form 470-5409 238.47 KB |
|
2016/06/22 |
|
Rifaximin (Xifaxan) PA Form 470-5411 235.8 KB |
|
2016/06/22 |
|
Long-Acting Opioids PA form 470-4409 240.23 KB |
|
2016/06/22 |
|
Non-Parenteral Vasopressin Derivatives PA 470-4107 257.36 KB |
|
2016/04/26 |
|
Non-Steroidal Anti-Inflammatory Drugs PA Form 470-4109 196.36 KB |
|
2016/04/26 |
|
Sodium Oxybate (Xyrem) PA Form 470-5016 249.1 KB |
|
2016/04/26 |
|
PCSK9 Inhibitors PA Form 470-5399 294.12 KB |
|
2016/04/25 |
|
Valsartan/Sacubitril (Entresto) PA Form 470-5398 204.66 KB |
|
2016/04/25 |
|
Cholic Acid (Cholbam) PA Form 470-5391 280.27 KB |
|
2016/03/08 |
|
Binge Eating Disorder Agents PA Form 470-5336 238.27 KB |
|
2016/03/08 |
|
Isotretinoin (Oral) PA Form 470-4101 31.76 KB |
|
2015/11/24 |
|
Granulocyte Colony Stimulating Factor PA Form 470-4099 23.67 KB |
|
2015/11/24 |
|
Biologicals for Inflammatory Bowel Disease PA Form 470-4523 28.96 KB |
|
2015/11/24 |
|
Linezolid (Zyvox) PA Form 470-4275 31.85 KB |
|
2015/11/24 |
|
Select Oncology Agents PA Form 470-5367 182.43 KB |
|
2015/11/23 |
|
Topical Antifungals for Onychomycosis PA Form 470-5368 177.29 KB |
|
2015/11/23 |
|
Alpha1-Proteinase Inhibitor Enzymes PA Form 470-5365 237 KB |
|
2015/11/23 |
|
Pavilizumab PA Form 470-4110 24.68 KB |
Palivizumab (Synagis®) approval periods will begin November 1, 2017 and will be considered through March 31, 2018. A maximum of five doses will be allowed per member during this time period. No allowances will be made for a sixth dose. Requests may be submitted beginning October 16, 2017 for a therapy start date of November 1, 2017. |
2015/09/17 |
|
Idiopathic Pulmonary Fibrosis PA Form 470-5346 70.34 KB |
|
2015/08/27 |
|
Topical Corticosteroids PA Form 470-5347 22.21 KB |
|
2015/08/27 |
|
Kalydeco (ivacaftor) PA Form 470-5117 32.52 KB |
|
2015/08/26 |
|
Immunomodulators - Topical PA Form 470-5040 52.86 KB |
|
2015/08/26 |
|
Dextromethorphan and Quinidine (Nuedexta™) PA Form 470-5084 30.17 KB |
|
2015/06/04 |
|
Chronic Pain Syndromes PA Form 470-4551 31.58 KB |
|
2015/06/04 |
|
Sedative/Hypnotic-Non_benzodiazepine PA Form 470-4328 28.77 KB |
|
2015/06/04 |
|
Apremilast (Otezla) PA Form 470-5293 62.27 KB |
|
2015/04/21 |
|
Benzodiazepines PA Form 470-4117 32.44 KB |
|
2015/04/21 |
|
Oral Immunotherapy PA Form 470-5295 28.8 KB |
|
2015/04/21 |
|
Methotrexate Injection PA Form 470-5294 28.97 KB |
|
2015/04/21 |
|
Thrombopoietin Receptor Agonists PA Form 470-4850 73.62 KB |
|
2015/04/21 |
|
Vorapaxar (Zontivity) PA Form 470-5331 23.4 KB |
|
2015/04/17 |
|
Growth Hormone PA Form 470-4100 205.4 KB |
|
2015/03/08 |
|
Tasimelteon (Hetlioz) PA Form 470-5296 22.64 KB |
|
2014/11/24 |
|
Antidepressant PA Form 470-5098 23.17 KB |
|
2014/06/12 |
|
Proton Pump Inhibitors PA Form 470-4112 27.56 KB |
|
2014/04/23 |
|
Antihistamines PA Form 470-4095 21.13 KB |
|
2014/04/23 |
|
Lidocaine Patch (Lidoderm) PA Form 470-4898 22.11 KB |
|
2014/04/23 |
|
Repository Corticotropin Injection PA Form 470-5172 19.2 KB |
|
2013/08/26 |
|
Erythropoesis Stimulating Agents PA Form 470-4098 72.46 KB |
|
2013/03/18 |
|
Korlym (mifepristone) PA Form 470-5141 19.78 KB |
|
2013/01/16 |
|
Ketorolac PA Form 470-4102 22.66 KB |
|
2012/06/26 |
|
Nebivolol (Bystolic) PA Form 470-5099 17.28 KB |
|
2012/03/13 |
|
Roflumilast (Daliresp™) PA Form 470-5085 56.57 KB |
|
2011/12/28 |
|
Muscle Relaxants PA Form 470-4105 19.17 KB |
|
2011/09/12 |
|
Fifteen Day Initial Prescription Supply Override PA Form 470-5038 14.22 KB |
|
2011/07/11 |
|
Non-Preferred Drug PA Form 470-4108 13.86 KB |
|
2011/06/16 |
|
Vitamins Minerals and Multiple Vitamins PA Form 470-4115 13.95 KB |
|
2011/06/16 |
|
Dalfampridine (Ampyra) PA Form 470-5015 17.63 KB |
|
2011/02/11 |
|
Quantity Limit Override Form 470-4556 96.04 KB |
|
2010/10/06 |
|
Amylino Mimetic PA Form 470-4406 33.02 KB |
|
2009/12/09 |
|
Febuxostat (Uloric) PA Form 470-4849 34.86 KB |
|
2009/10/02 |
|
Narcotic Agonist Antagonist Nasal Spray PA Form 470-4106 33.79 KB |
|
2009/07/27 |
|
Vusion Ointment PA form 470-4655 27.19 KB |
|
2008/12/11 |
|
Becaplermin (Regranex) PA Form 470-4276 47.11 KB |
|
2008/09/05 |
|
Miscellaneous PA Form 470-4104 29.29 KB |
|
2007/12/26 |